SSA
SIOX

Schonfeld Strategic Advisors’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-4,454
Closed -$245K – 926
2017
Q3 		$245K Buy
4,454
+345
+8% +$58.2K 0.02% 491
2017
Q2 		$762K Buy
+4,109
New +$720K 0.08% 322
2016
Q3 		– Sell
-3,061
Closed -$314K – 587
2016
Q2 		$314K Buy
+3,061
New +$306K 0.07% 308

Other funds holding SIOX

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
IA
IPL Advisers New York $158M AUM 18.16% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IPLA
Ice Pond Lane Advisers New York $7.38M AUM 1.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Schonfeld Strategic Advisors's SIOX Position: Q4 2017 in Review

Schonfeld Strategic Advisors sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2017, closing a stake of 4,454 shares — an estimated $245K sold.

Schonfeld Strategic Advisors first reported a position in SIOX in Q2 2016 and held it in 3 quarters. The position peaked at $762K in Q2 2017. 104 funds tracked by Wall St. Rank hold SIOX as of Q4 2017.

  • Schonfeld Strategic Advisors reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 4,454 Sio Gene Therapies Inc. Common Stock shares in Q4 2017, an estimated $245K.
  • Schonfeld Strategic Advisors first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2016 and held it in 3 quarters.
  • Schonfeld Strategic Advisors's Sio Gene Therapies Inc. Common Stock position peaked at $762K in Q2 2017.
  • 104 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2017.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.